The primary aim of the Core C facility is synthesis of chemical building blocks (or intermediates) to facilitatethe generation of Focused Chemical Libraries in Projects 1, 2, 3, 4 & 5 of the P01 program and to assistProjects 1, 2, 3, 4 and 5 with multi-gram scale re-synthesis of lead compounds for their in-vivo animalstudies. The specific functions of Core C will include: The synthesis of unique chemical building blocks that are not commercially available for use by the projects for combinatorial and parallel chemistry. The chemical space explored by Projects 1, 2, 3, 4 and 5, via the synthesis of combinatorial libraries, will therefore be expanded in an efficient and exclusive manner. The multi-gram scale re-synthesis of lead and key compounds for advanced drug property studies within the projects to evaluate in-vivo activity, toxicity, selectivity, metabolism and molecular mechanism.The compounds chosen as leads from Projects 1, 2, 3, 4 and 5 need to be re-synthesized with the highestlevels of purities (at least 99% pure by HPLC) possible. It is time consuming to validate the reactionconditions, purification and analytical techniques (HPLC and LCMS) necessary to provide pure materials.Researchers whose primary responsibility is lead discovery and optimization would have to devote aconsiderable amount of time to the re-synthesis of a particular target compound, which could have anadverse effect on their primary goal.Molecular diversity within a combinatorial library is created by attaching chemical building blocks to scaffoldsor intermediates. This diversity is highly dependent upon the quality of the building block set used within thelibrary. By providing new building blocks, novel chemical and biological space can be probed, therebyincreasing the chances of discovering new highly potent anticancer agents. Flexible synthetic routes will bedeveloped that provide novel building blocks designed to incorporate drug-like properties. Whereverpossible the building blocks and their derivatives will be shared across the projects.For these reasons, chemical building block synthesis and multi-gram scale re-synthesis support will play akey role in both integrating the different projects and in achieving the goals of the P01 in identifying a numberof potent and selective compounds as tools to fully investigate the biological significance of their signaltransduction targets in Projects 1, 2, 3, 4 and 5 and for pre-clinical evaluation as anticancer drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA118210-01A1
Application #
7214964
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O4))
Project Start
2006-12-01
Project End
2011-11-30
Budget Start
2006-12-01
Budget End
2008-01-31
Support Year
1
Fiscal Year
2007
Total Cost
$123,658
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Kazi, Aslamuzzaman; Ozcan, Sevil; Tecleab, Awet et al. (2014) Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem 289:11906-15
Ozcan, Sevil; Kazi, Aslamuzzaman; Marsilio, Frank et al. (2013) Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors. J Med Chem 56:3783-805
Treviño, José G; Verma, Monika; Singh, Sandeep et al. (2013) Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Mol Cancer Ther 12:2722-34
Ge, Yiyu; Kazi, Aslamuzzaman; Marsilio, Frank et al. (2012) Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. J Med Chem 55:1978-98
Davis, Rebecca; Pillai, Smitha; Lawrence, Nicholas et al. (2012) TNF-?-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes. Cell Cycle 11:109-18
Kim, Young B; Balasis, Maria E; Doi, Kenichiro et al. (2012) Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction. Bioorg Med Chem Lett 22:5961-5
Johnson, Jackie L; Pillai, Smitha; Pernazza, Danielle et al. (2012) Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res 72:516-26
Doi, Kenichiro; Li, Rongshi; Sung, Shen-Shu et al. (2012) Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 287:10224-35
Li, X; Gilkes, D; Li, B et al. (2012) Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene 31:3721-32
Win-Piazza, Hla; Schneeberger, Valentina E; Chen, Liwei et al. (2012) Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2. Cancer Lett 320:81-5

Showing the most recent 10 out of 39 publications